公开(公告)号：WO2008143649A3

公开(公告)日：2008-11-27

申请号：PCT/US2007/024843

申请日：2007-12-04

Applicant: DR. REDDY'S LABORATORIES LIMITED ,  DR. REDDY'S LABORATORIES, INC. ,  TAKHI, Mohamed ,  DAS, Jagattaran ,  IQBAL, Javed ,  SELVAKUMAR, Natesan ,  KANDEPU, Sreenivas ,  KUMAR, M., Sitaram

Inventor： TAKHI, Mohamed ,  DAS, Jagattaran ,  IQBAL, Javed ,  SELVAKUMAR, Natesan ,  KANDEPU, Sreenivas ,  KUMAR, M., Sitaram

IPC: A01N65/00

Abstract: The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents

公开(公告)号：WO2007005785B1

公开(公告)日：2007-03-22

申请号：PCT/US2006025898

申请日：2006-06-30

Applicant: REDDYS LAB LTD DR ,  REDDYS LAB INC DR ,  POTLURI VIJAY KUMAR ,  DAS SAIBAL KUMAR ,  SASMAL PRADIP KUMAR ,  IQBAL JAVED ,  MISRA PARIMAL ,  CHAKRABARTI RANJAN ,  TALWAR RASHMI

Inventor： POTLURI VIJAY KUMAR ,  DAS SAIBAL KUMAR ,  SASMAL PRADIP KUMAR ,  IQBAL JAVED ,  MISRA PARIMAL ,  CHAKRABARTI RANJAN ,  TALWAR RASHMI

IPC: C07D277/14 ,  A61K31/426 ,  A61K31/5377 ,  C07D265/32

CPC classification number: C07D277/42

Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5'-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Abstract translation: 本申请提供了可用作腺苷5'-单磷酸激活蛋白激酶的激活剂的新型噻唑衍生物和含有这些化合物的药物组合物。

公开(公告)号：WO2006073610A2

公开(公告)日：2006-07-13

申请号：PCT/US2005/042736

申请日：2005-11-23

Applicant: REDDY US THERAPEUTICS, INC. ,  PAL, Manojit ,  RAO, Yeleswarapu, Koteswar ,  KHANNA, Ish, Kumar ,  SWAMY, Nalivela, Kumara ,  SUBRAMANIAN, Venkataraman ,  BATCHU, Venkateswara, Rao ,  IQBAL, Javed ,  PILLARISETTI, Sivaram

Inventor： PAL, Manojit ,  RAO, Yeleswarapu, Koteswar ,  KHANNA, Ish, Kumar ,  SWAMY, Nalivela, Kumara ,  SUBRAMANIAN, Venkataraman ,  BATCHU, Venkateswara, Rao ,  IQBAL, Javed ,  PILLARISETTI, Sivaram

IPC: A61K31/519 ,  C07D487/02

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.

Abstract translation: 除其他之外，本发明提供了新的双环杂环化合物，包含这些杂环化合物的组合物，制备该杂环化合物的方法以及使用这些杂环化合物治疗多种病症和疾病的方法 例如与细胞增殖，炎症，糖苷酶表达或者基底膜蛋白聚糖的低表达有关的状态。

公开(公告)号：WO2006034474A2

公开(公告)日：2006-03-30

申请号：PCT/US2005/034244

申请日：2005-09-23

Applicant: REDDY US THERAPEUTICS, INC. ,  KALLEDA, Srinivas ,  PADAKANTI, Srinivas ,  KUMARSAMY, Nalivela ,  ALEXANDER, Christopher W. ,  KHANNA, Ish ,  IQBAL, Javed ,  PILLARISETTI, Ram ,  MAITRA, Santanu ,  ROBERTS, Gayla, R. ,  SAGI, Lavanya

Inventor： KALLEDA, Srinivas ,  PADAKANTI, Srinivas ,  KUMARSAMY, Nalivela ,  ALEXANDER, Christopher W. ,  KHANNA, Ish ,  IQBAL, Javed ,  PILLARISETTI, Ram ,  MAITRA, Santanu ,  ROBERTS, Gayla, R. ,  SAGI, Lavanya ,  YELESWARAPU, Koteswar Rao

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/44 ,  C07D417/02 ,  C07D403/02 ,  C07D413/02 ,  C07D401/02

CPC classification number: C07D405/14 ,  C07D239/30 ,  C07D239/40 ,  C07D239/42 ,  C07D239/46 ,  C07D239/47 ,  C07D239/48 ,  C07D239/50 ,  C07D239/54 ,  C07D401/04 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

Abstract translation: 本发明提供新的杂环化合物，特别是取代的吡啶，制备和使用这些杂环化合物的方法和组合物，以及用于治疗各种疾病和疾病状态的方法，包括动脉粥样硬化，关节炎，再狭窄，糖尿病性肾病或血脂异常或疾病 由Perlecan低表达介导的状态。

公开(公告)号：WO2006029075A3

公开(公告)日：2006-03-16

申请号：PCT/US2005/031532

申请日：2005-09-06

Applicant: DR. REDDY'S LABORATORIES LTD. ,  DR. REDDY'S LABORATORIES, INC. ,  DAS, Saibal Kumar ,  SINGH, Sunil Kumar ,  MADHAVAN, Gurram, Ranga ,  BHUNIYA, Debnath ,  IQBAL, Javed ,  SHARMA, Sudhir, Kumar ,  CHAKRABARTI, Ranjan

Inventor： DAS, Saibal Kumar ,  SINGH, Sunil Kumar ,  MADHAVAN, Gurram, Ranga ,  BHUNIYA, Debnath ,  IQBAL, Javed ,  SHARMA, Sudhir, Kumar ,  CHAKRABARTI, Ranjan

IPC: C07D487/04 ,  C07D239/90 ,  A61K31/519 ,  A61K31/517 ,  C07D231/14 ,  C07D231/38 ,  C07C59/48 ,  C07C59/01 ,  C07C69/003 ,  C07C43/205

Abstract: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from -CH 2 -, -O-, -NH-, and -S-; Y is chosen from -O-, -NH-, and -S-; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARα agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARα agonist activity and a PPARα agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.

公开(公告)号：WO2004069145A3

公开(公告)日：2004-08-19

申请号：PCT/IB2004/000299

申请日：2004-02-06

Applicant: DR. REDDY'S LABORATORIES LTD. ,  VEDULA, Manohar, Sharma ,  KATTUBOINA, Venkata, Adiseshu ,  IQBAL, Javed ,  RAMANUJAM, Rajagopalan ,  RAJAGOPAL, Sriram ,  MAMIDI, Naga, Venkata, Srinivasa, Rao ,  JOSYULA, Ramanatham ,  GUTTA, Madhusudhan

Inventor： VEDULA, Manohar, Sharma ,  KATTUBOINA, Venkata, Adiseshu ,  IQBAL, Javed ,  RAMANUJAM, Rajagopalan ,  RAJAGOPAL, Sriram ,  MAMIDI, Naga, Venkata, Srinivasa, Rao ,  JOSYULA, Ramanatham ,  GUTTA, Madhusudhan

IPC: C07D215/00

Abstract: The present invention relates to novel anticancer agents, their pharmaceutically acceptable salts, their geometrical isomers and their pharmaceutically acceptable compositions containing them. the present invention more particularly relates to novel quinazoline compounds, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions containing them. the novel quinazoline compounds have the general formula (I), where all symbols are as defined in the specification.

公开(公告)号：WO2003048116A3

公开(公告)日：2003-06-12

申请号：PCT/IB2002/005064

申请日：2002-12-02

Applicant: DR. REDDY'S LABORATORIES LTD. ,  BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  MADHAVAN, Gurram, Ranga ,  IQBAL, Javed ,  CHAKRABARTI, Ranjan ,  VIKRAMADITHYAN, Reeba, Kannimel

Inventor： BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  MADHAVAN, Gurram, Ranga ,  IQBAL, Javed ,  CHAKRABARTI, Ranjan ,  VIKRAMADITHYAN, Reeba, Kannimel

IPC: C07C309/66

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to compounds of the general formula (I) which are predominantly PPAR alpha agonists, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them The present invention also relates to processes for the preparation of novel compounds of formula (I), novel intermediates, processes for their preparation, use of the novel intermediates in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.

公开(公告)号：WO2003033481A1

公开(公告)日：2003-04-24

申请号：PCT/IB2002/004275

申请日：2002-10-15

Applicant: DR. REDDY'S LABORATORIES LTD. ,  BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  MADHAVAN, Gurram, Ranga ,  IQBAL, Javed ,  CHAKRABARTI, Ranjan

Inventor： BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  MADHAVAN, Gurram, Ranga ,  IQBAL, Javed ,  CHAKRABARTI, Ranjan

IPC: C07D265/36

CPC classification number: C07C229/42 ,  C07C229/34 ,  C07D265/36 ,  C07D279/16

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.

Abstract translation: 本发明涉及式I的新型抗糖尿病，降血脂，抗胆固醇和低胆固醇血症的衍生物，其类似物，其互变异构形式，其立体异构体，其多晶型物，其药学上可接受的盐，其药学上可接受的溶剂化物和含有它们的药学上可接受的组合物， 制备这种化合物的方法。 更具体地说，本发明涉及通用的衍生物，其衍生物，它们的类似物，它们的互变异构形式，它们的立体异构体，它们的多晶型物，其药学上可接受的盐，其药学上可接受的溶剂化物和含有它们的药学上可接受的组合物的新型烷基羧酸， 制备此类化合物的方法。 本发明还涉及制备式I化合物的方法，新型中间体，其制备方法，它们在制备上述化合物中的用途及其作为抗糖尿病，降血脂症，抗肥胖症和低胆固醇血症化合物的用途。

公开(公告)号：US20120258170A1

公开(公告)日：2012-10-11

申请号：US13423728

申请日：2012-03-19

Applicant: Anil Kumar KRUTHIVENTI ,  Iqbal Javed ,  Satyanarayana Reddy Jaggavarapu ,  RaviKumar Nagalapalli ,  Ganesh Saraswatula Viswanadha ,  Solomon Kamalakaran Anand

Inventor： Anil Kumar KRUTHIVENTI ,  Iqbal Javed ,  Satyanarayana Reddy Jaggavarapu ,  RaviKumar Nagalapalli ,  Ganesh Saraswatula Viswanadha ,  Solomon Kamalakaran Anand

IPC: A61K31/353 ,  C07D487/04 ,  A61K31/4985 ,  C07D207/16 ,  A61K31/40 ,  C07F5/02 ,  A61K31/69 ,  C07D209/52 ,  A61K31/403 ,  C07D473/04 ,  A61K31/522 ,  C07D471/04 ,  A61K31/519 ,  C07D401/04 ,  A61K31/506 ,  A61K31/55 ,  A61K31/4965 ,  A61K31/4015 ,  A61K31/7036 ,  A61K31/4439 ,  A61K31/44 ,  A61K9/20 ,  A61P27/12 ,  A61P3/00 ,  A61P9/12 ,  A61P3/10 ,  A61P3/06 ,  A61P3/04 ,  C07D311/32

CPC classification number: C07D311/32 ,  A61K9/14 ,  C07D311/28 ,  C07D311/62

Abstract: A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.

Abstract translation: 由槲皮素和至少一种抗糖尿病剂组成的共晶组合物作为具有独特物理性质和生物活性的组合药物，其与纯形式的槲皮素和纯形式的至少一种抗糖尿病药物不同。 共晶组合物可以包含槲皮素和二甲双胍。 槲皮素和二甲双胍的共晶可以通过研磨化合物制备，并用于包含这些共晶体的药物组合物中。 槲皮素和二甲双胍的共晶组合物可与其它抗糖尿病药物（包括DPP-IV抑制剂）组合使用。

公开(公告)号：US20070093476A1

公开(公告)日：2007-04-26

申请号：US10577698

申请日：2004-10-20

Applicant: Bhunia Debnath ,  Ranga Gurram ,  Das Saibal Kumar ,  Iqbal Javed ,  Chakrabarti Ranjan ,  Kole Labanyamoy

Inventor： Bhunia Debnath ,  Ranga Gurram ,  Das Saibal Kumar ,  Iqbal Javed ,  Chakrabarti Ranjan ,  Kole Labanyamoy

IPC: A61K31/5415 ,  A61K31/538 ,  A61K31/4704 ,  A61K31/404 ,  A61K31/195

CPC classification number: C07C311/08 ,  C07C37/002 ,  C07C39/17 ,  C07C45/30 ,  C07C69/712 ,  C07C69/757 ,  C07C205/22 ,  C07C205/37 ,  C07C205/56 ,  C07C217/86 ,  C07C271/28 ,  C07C309/66 ,  C07C309/73 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/10 ,  C07D209/08 ,  C07D215/06 ,  C07D265/36 ,  C07C47/575 ,  C07C39/11

Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p′(CH2)pB(CH2)q′(CH2)rB(CH2)pD(CH2)p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, —S(O)2—R8 or —C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.